UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Blood, 2011-11, Vol.118 (18), p.4771-4779

2011

Volltextzugriff (PDF)

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Blood, 2012-10, Vol.120 (16), p.3260-3270

2012

Volltextzugriff (PDF)

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737

PloS one, 2014-09, Vol.9 (9), p.e103015

2014

Volltextzugriff (PDF)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Leukemia, 2020-04, Vol.34 (4), p.1197-1201

2020

Volltextzugriff (PDF)

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples

Applied immunohistochemistry & molecular morphology, 2016-11, Vol.24 (10), p.695-702

2016

Volltextzugriff (PDF)

Stable DNA−Protein Cross-Links Are Products of DNA Charge Transport in a Nucleosome Core Particle

Biochemistry (Easton), 2007-09, Vol.46 (38), p.10745-10755

2007

Volltextzugriff (PDF)

Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma

British journal of haematology, 2016-03, Vol.172 (6), p.889-901

2016

Volltextzugriff (PDF)

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

The Journal of biological chemistry, 2011-04, Vol.286 (13), p.11009-11020

2011

Volltextzugriff (PDF)

Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA

Molecular cancer therapeutics, 2012-10, Vol.11 (10), p.2243-2253

2012

Volltextzugriff (PDF)

Probing the Effects of DNA–Protein Interactions on DNA Hole Transport: The N-Terminal Histone Tails Modulate the Distribution of Oxidative Damage and Chemical Lesions in the Nucleosome Core Particle

Biochemistry (Easton), 2012-04, Vol.51 (14), p.3129-3142

2012

Volltextzugriff (PDF)

The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1

The Journal of pharmacology and experimental therapeutics, 2013-09, Vol.346 (3), p.381-392

2013

Volltextzugriff (PDF)

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

Clinical cancer research, 2015-06, Vol.21 (11), p.2538-2545

2015

Volltextzugriff (PDF)

Hole Transport Dynamics in Mixed Sequence DNA Can Vary with Salt Concentration: An Experimental and Theoretical Analysis

Journal of physical chemistry. C, 2010-12, Vol.114 (48), p.20821-20833

2010

Volltextzugriff (PDF)

Attenuation of DNA charge transport by compaction into a nucleosome core particle

Nucleic acids research, 2006-01, Vol.34 (6), p.1836-1846

2006

Volltextzugriff (PDF)

Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL

Blood, 2023-11, Vol.142 (Supplement 1), p.5719-5719

2023

Volltextzugriff (PDF)

Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo

Molecular cancer therapeutics, 2011-01, Vol.10 (1), p.148-158

2011

Volltextzugriff (PDF)

Targeting the Pro-Survival Protein c-MET With ARQ 197 Inhibits Growth of Multiple Myeloma Cells

Clinical lymphoma, myeloma and leukemia, 2013-09, Vol.13, p.S381-S381

2013

Volltextzugriff (PDF)

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Blood, 2023-11, Vol.142 (Supplement 1), p.3295-3295

2023

Volltextzugriff (PDF)

Mechanistic Insights of Pomalidomide Activity in Combination with Bortezomib and Dexamethasone in Multiple Myeloma and Immune Cells

Blood, 2018-11, Vol.132 (Supplement 1), p.1934-1934

2018

Volltextzugriff (PDF)

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

Leukemia, 2014-02, Vol.28 (2), p.373-383

2014

Volltextzugriff (PDF)

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Blood, 2023-11, Vol.142 (Supplement 1), p.3289-3289

2023

Volltextzugriff (PDF)

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2/M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2669-2669

2021

Volltextzugriff (PDF)

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Blood, 2019-11, Vol.134 (Supplement_1), p.4406-4406

2019

Volltextzugriff (PDF)

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.3318-3318

2023

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(54)
Tagungsberichte
(1)

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(16)
Humans
(13)
Cell Line, Tumor
(9)
Animals
(7)
Multiple Myeloma - Drug Therapy
(7)
Apoptosis - Drug Effects
(6)
Hematology
(6)
Multiple Myeloma
(6)
Oncology
(6)
Thalidomide - Analogs & Derivatives
(6)
Multiple Myeloma - Genetics
(5)
Multiple Myeloma - Pathology
(5)
Biochemistry & Molecular Biology
(4)
Drug Resistance, Neoplasm - Drug Effects
(4)
Female
(4)
Lenalidomide
(4)
Mice
(4)
Mice, Scid
(4)
Multiple Myeloma - Metabolism
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples

Stable DNA−Protein Cross-Links Are Products of DNA Charge Transport in a Nucleosome Core Particle

Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA

Probing the Effects of DNA–Protein Interactions on DNA Hole Transport: The N-Terminal Histone Tails Modulate the Distribution of Oxidative Damage and Chemical Lesions in the Nucleosome Core Particle

The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

Hole Transport Dynamics in Mixed Sequence DNA Can Vary with Salt Concentration: An Experimental and Theoretical Analysis

Attenuation of DNA charge transport by compaction into a nucleosome core particle

Investigation of the Synergistic Combination of a Novel Celmod (CC-99282) and BET Inhibitors in Preclinical DLBCL

Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo

Targeting the Pro-Survival Protein c-MET With ARQ 197 Inhibits Growth of Multiple Myeloma Cells

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Mechanistic Insights of Pomalidomide Activity in Combination with Bortezomib and Dexamethasone in Multiple Myeloma and Immune Cells

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2/M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Suchergebnisse filtern